• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Intricon Corporation (Amendment)

    2/10/22 8:17:19 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care
    Get the next $IIN alert in real time by email
    SC 13G/A 1 tv01184-intriconcorp.htm SCHEDULE 13G/A intriconcorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  IntriCon Corp.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  46121H109

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  46121H109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    1,302

    7.  SOLE DISPOSITIVE POWER

    396,355

    8.  SHARED DISPOSITIVE POWER

    4,594

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    400,949

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.39%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    IntriCon Corp.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1260 Red Fox Road
    Arden Hills, MN 55113

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    46121H109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $IIN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IIN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Giordano Nicholas A gifted 4,000 shares and returned 110,925 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:49:14 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Smith Philip Irving returned 16,327 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:43:53 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Gorder Mark Stephen returned 373,709 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:46:42 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $IIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $IIN
    SEC Filings

    View All

    B. Riley resumed coverage on IntriCon with a new price target

    B. Riley resumed coverage of IntriCon with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    2/26/21 9:37:25 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Announces Completion of Acquisition by an Affiliate of Altaris Capital Partners

    ARDEN HILLS, Minn., May 24, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced the completion of its acquisition by funds affiliated with Altaris Capital Partners, LLC (together with certain affiliated entities, "Altaris") for $24.25 per share in cash, or approximately $241 million on a fully diluted basis. The transaction was announced on February 28, 2022, and received approval from stockholders on May 24, 2022. As a result of the transaction, Intricon is now a privately he

    5/24/22 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Reports Fourth Quarter and Full Year 2021 Results

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di

    2/28/22 8:40:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Enters into Agreement to be Acquired by an Affiliate of Altaris Capital Partners for $241 Million

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced that it has entered into a definitive agreement whereby an affiliate of Altaris Capital Partners, LLC (collectively with its affiliates, "Altaris"), an investment firm focused exclusively on the healthcare industry, will acquire the company. Under the terms of the agreement, Altaris will acquire all outstanding shares of Intricon for $24.25 per share in a transaction that values Intricon at an equ

    2/28/22 8:35:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12B filed by Intricon Corporation

    15-12B - INTRICON CORP (0000088790) (Filer)

    6/3/22 10:36:21 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INTRICON CORP (0000088790) (Filer)

    5/25/22 3:55:57 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Intricon Corporation

    S-8 POS - INTRICON CORP (0000088790) (Filer)

    5/24/22 5:07:27 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Financials

    Live finance-specific insights

    View All

    Intricon Reports Fourth Quarter and Full Year 2021 Results

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di

    2/28/22 8:40:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Reports Third Quarter 2021 Results

    ARDEN HILLS, Minn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its third quarter ended September 30, 2021. Third Quarter 2021 Highlights: Revenue of $31.1 million, a 13.5% increase compared to the prior year periodGross profit margin of 23.1%, compared to 26.3% in the prior year periodGAAP net income of $337,000 versus net income of $644,000 in the prior year periodNon-GAAP adjusted net income of $1.7 million versus $2.4 m

    11/8/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Announces CFO Departure and Preliminary Third Quarter 2021 Revenue

    ARDEN HILLS, Minn., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, announced today that Ellen Scipta has stepped down from her position as Chief Financial Officer, effective October 29, 2021. Annalee Lutgen, current Treasurer and Director of Finance, will serve as interim Chief Financial Officer effective upon Ms. Scipta's resignation as the company conducts its search for a permanent replacement. "We appreciate the contributions Ellen has made to Intricon during her tenure h

    10/29/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Leadership Updates

    Live Leadership Updates

    View All

    Intricon Appoints Kathleen Pepski to its Board of Directors Intricon Corporation

    ARDEN HILLS, Minn., March 22, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced the appointment of Kathleen Pepski to the company’s Board of Directors, effective March 19, 2021. “We are delighted to welcome Kathleen to Intricon and our board of directors,” said Scott Longval, President and Chief Executive Officer of Intricon. “Kathleen is a well-respected business leader in Minneapolis whose background in manufacturing and distribution, as well as mergers and acquisitions, will be instrumental in our long

    3/22/21 8:00:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Corporation Announces Appointment of Chief Financial Officer

    ARDEN HILLS, Minn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that Ellen Scipta has been appointed Chief Financial Officer (CFO), effective immediately. As a key member of Intricon's executive leadership team, Ms. Scipta will lead the company’s financial operations and aid the management team on growing Intricon. “We are extremely pleased to welcome a strong leader like Ellen to the Intricon team. Her unique skill set that blends engineering with extensive financial experience will be inva

    2/8/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/26/22 4:04:17 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/23/22 4:14:23 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/19/22 4:06:37 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care